On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Ty Roush is a breaking news reporter based in New York City. Eli Lilly on Monday lowered the cost of Zepbound after the pharmaceutical giant and Ozempic maker Novo Nordisk announced a deal with the ...

Eli Lilly made a move that could help address a drawback of its anti-obesity medicines. This could help it fend off mounting competition in this fast-growing area. Lilly's business extends far beyond ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

Eli Lilly is releasing new Phase 3 trial results Tuesday. Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

Eli Lilly's growth is impressive, driven by Mounjaro and Zepbound, but its current valuation is only justifiable with sustained high growth. Despite strong results and superior products, Eli Lilly is ...

Shares of the gene therapy developer rose 12.5% to $9.55 in premarket trading on Monday after the news. Sign up here. Under the deal, MeiraGTx will get an upfront payment of $75 million and ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...